CNY 14.29
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 24.37 Billion CNY | 19.47% |
2022 | 18.6 Billion CNY | -5.58% |
2021 | 19.7 Billion CNY | 45.25% |
2020 | 13.56 Billion CNY | 20.52% |
2019 | 11.25 Billion CNY | 997.78% |
2018 | 1.02 Billion CNY | 5.41% |
2017 | 972.92 Million CNY | 11.29% |
2016 | 874.21 Million CNY | -8.41% |
2015 | 954.47 Million CNY | -21.67% |
2014 | 1.21 Billion CNY | -7.4% |
2013 | 1.31 Billion CNY | -29.04% |
2012 | 1.85 Billion CNY | 6.77% |
2011 | 1.73 Billion CNY | 23.43% |
2010 | 1.4 Billion CNY | -15.72% |
2009 | 1.66 Billion CNY | 2.88% |
2008 | 1.62 Billion CNY | 24.89% |
2007 | 1.29 Billion CNY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 6.71 Billion CNY | 5.81% |
2024 Q1 | 6.34 Billion CNY | 26.88% |
2024 Q3 | 7.09 Billion CNY | 5.69% |
2023 FY | 22.22 Billion CNY | 19.47% |
2023 Q3 | 5.47 Billion CNY | -10.49% |
2023 Q4 | 5 Billion CNY | -8.59% |
2023 Q2 | 6.11 Billion CNY | 8.38% |
2023 Q1 | 5.64 Billion CNY | -4.0% |
2022 Q4 | 5.87 Billion CNY | 59.17% |
2022 Q3 | 3.69 Billion CNY | 13.06% |
2022 Q2 | 3.26 Billion CNY | -43.44% |
2022 Q1 | 5.77 Billion CNY | 97.04% |
2022 FY | 18.6 Billion CNY | -5.58% |
2021 FY | 19.7 Billion CNY | 45.25% |
2021 Q4 | 2.92 Billion CNY | -45.73% |
2021 Q2 | 4.97 Billion CNY | -22.38% |
2021 Q1 | 6.4 Billion CNY | 86.39% |
2021 Q3 | 5.39 Billion CNY | 8.58% |
2020 FY | 13.56 Billion CNY | 20.52% |
2020 Q3 | 3.45 Billion CNY | 17.13% |
2020 Q2 | 2.94 Billion CNY | -20.98% |
2020 Q1 | 3.73 Billion CNY | 32.11% |
2020 Q4 | 3.43 Billion CNY | -0.47% |
2019 Q3 | 2.7 Billion CNY | 9.0% |
2019 FY | 11.25 Billion CNY | 997.78% |
2019 Q1 | 3.25 Billion CNY | 1235.25% |
2019 Q2 | 2.47 Billion CNY | -23.85% |
2019 Q4 | 2.82 Billion CNY | 4.52% |
2018 FY | 1.02 Billion CNY | 5.41% |
2018 Q4 | 243.75 Million CNY | -21.12% |
2018 Q3 | 309.02 Million CNY | 5.69% |
2018 Q2 | 292.38 Million CNY | 62.08% |
2018 Q1 | 180.39 Million CNY | -7.79% |
2017 Q4 | 195.62 Million CNY | -27.11% |
2017 FY | 972.92 Million CNY | 11.29% |
2017 Q1 | 192.46 Million CNY | -1.92% |
2017 Q2 | 316.42 Million CNY | 64.41% |
2017 Q3 | 268.4 Million CNY | -15.18% |
2016 Q2 | 265.21 Million CNY | 25.65% |
2016 FY | 874.21 Million CNY | -8.41% |
2016 Q4 | 196.23 Million CNY | -2.7% |
2016 Q3 | 201.68 Million CNY | -23.95% |
2016 Q1 | 211.07 Million CNY | 25.53% |
2015 FY | 954.47 Million CNY | -21.67% |
2015 Q1 | 283.85 Million CNY | -2.35% |
2015 Q2 | 284.78 Million CNY | 0.33% |
2015 Q3 | 217.69 Million CNY | -23.56% |
2015 Q4 | 168.15 Million CNY | -22.76% |
2014 Q2 | 358.76 Million CNY | 23.71% |
2014 FY | 1.21 Billion CNY | -7.4% |
2014 Q3 | 279.06 Million CNY | -22.21% |
2014 Q1 | 290 Million CNY | -10.16% |
2014 Q4 | 290.67 Million CNY | 4.16% |
2013 Q2 | 334.96 Million CNY | 18.72% |
2013 Q1 | 282.14 Million CNY | -44.37% |
2013 FY | 1.31 Billion CNY | -29.04% |
2013 Q4 | 322.81 Million CNY | -14.14% |
2013 Q3 | 375.99 Million CNY | 12.25% |
2012 Q2 | 437.74 Million CNY | -5.93% |
2012 FY | 1.85 Billion CNY | 6.77% |
2012 Q4 | 507.2 Million CNY | 14.23% |
2012 Q3 | 444.02 Million CNY | 1.44% |
2012 Q1 | 465.35 Million CNY | 17.87% |
2011 Q2 | 539.33 Million CNY | 49.41% |
2011 Q1 | 360.96 Million CNY | -9.42% |
2011 FY | 1.73 Billion CNY | 23.43% |
2011 Q3 | 441.69 Million CNY | -18.1% |
2011 Q4 | 394.81 Million CNY | -10.61% |
2010 FY | 1.4 Billion CNY | -15.72% |
2010 Q1 | 364.54 Million CNY | -15.01% |
2010 Q2 | 297.46 Million CNY | -18.4% |
2010 Q3 | 346.59 Million CNY | 16.52% |
2010 Q4 | 398.48 Million CNY | 14.97% |
2009 Q3 | 423.52 Million CNY | 0.59% |
2009 Q1 | 396.07 Million CNY | 0.0% |
2009 Q2 | 421.05 Million CNY | 6.31% |
2009 FY | 1.66 Billion CNY | 2.88% |
2009 Q4 | 428.93 Million CNY | 1.28% |
2008 FY | 1.62 Billion CNY | 24.89% |
2007 FY | 1.29 Billion CNY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Hubei Biocause Pharmaceutical Co., Ltd. | 49.72 Billion CNY | 50.979% |